Skip to main content

Table 1 Demographic, clinical, and cannabis-use characteristics of patients with past-month cannabis use

From: The association between cannabis use and outcome in pharmacological treatment for opioid use disorder

Characteristic

Total sample (N = 2313)

Cannabis non-user (n = 1135)

Cannabis user (n = 1178)

Demographic

   

 Age in years; mean (SD)

39.3 (10.9)

40.9 (10.9)

37.7 (10.6)

 Female sex; n (%)

1025 (44.3%)

557 (49.1%)

468 (39.7%)

 Married; n (%)

673 (29.1%)

356 (31.4%)

317 (26.9%)

 Unemployed; n (%)

1548 (66.9%)

761 (67.1%)

787 (66.8%)

Clinical

   

 Length of time in treatment, in years; median (Q1, Q3)

2.6 years (0.83, 6)

3 years (0.92, 7)

2 years (0.75, 6)

Type of treatment; n (%)

   

 Methadone

1833 (79.4%)

890 (78.6%)

944 (80.1%)

 Buprenorphine–naloxone

477 (20.7%)

243 (21.5%)

234 (19.9%)

Medication dose in mg/day; mean (SD)

   

 Methadone

70.4 mg (40.6)

72.9 mg (41.3)

68.1 mg (39.8)

 Buprenorphine–naloxnaloxone

12 mg (6.8)

12 mg (7.0)

12 mg (6.6)

 Opioid use at 3 monthsa; n (%)

1015 (44.8%)

488 (44.0%)

527 (44.7%)

 Percentage of opioid-positive urine drug screens amongst users; median (Q1, Q3)

25 (11.1, 50)

30 (12.5, 55.6)

21.4 (10, 50)

  1. SD standard deviation, MAT medication-assisted treatment, Q1 25th percentile, Q3 75th percentile
  2. aData available for n = 1155 participants